Zhu Fengge, Bai Xueyuan, Chen Xiangmei
Department of Nephrology, Chinese PLA General Hospital, Chinese PLA Institute of Nephrology, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Beijing, China.
J Cell Commun Signal. 2017 Sep;11(3):213-218. doi: 10.1007/s12079-017-0382-x. Epub 2017 Feb 16.
Fibrosis is defined as an excessive deposition of extracellular matrix (ECM), which leads to the destruction of organ structure and impairment of organ function. Fibrosis occurs not only in kidney but also in lung, liver, heart, and skin. Common pathways of fibrosis are thought to exist. Renal interstitial fibrosis is a complex process that involves multiple molecular signaling and multiple cellular components, in which B cells appear to be one of the emerging important players. B cells may affect fibrosis through cytokine production and through interaction with other cells including fibroblasts, macrophages and T cells. This review summarizes recent research findings of B cells in fibrosis and provides an insight of how the future therapeutics of fibrosis could be developed from a B-cell point of view.
纤维化被定义为细胞外基质(ECM)的过度沉积,这会导致器官结构破坏和器官功能受损。纤维化不仅发生在肾脏,也发生在肺、肝、心和皮肤。人们认为存在纤维化的常见途径。肾间质纤维化是一个复杂的过程,涉及多种分子信号传导和多种细胞成分,其中B细胞似乎是新出现的重要参与者之一。B细胞可能通过产生细胞因子以及与包括成纤维细胞、巨噬细胞和T细胞在内的其他细胞相互作用来影响纤维化。本综述总结了B细胞在纤维化方面的最新研究成果,并从B细胞的角度深入探讨了未来纤维化治疗方法的开发。